目的探讨贝飞达和思密达联合治疗新生儿高胆红素血症的临床疗效。方法回顾性分析我院近年来收治的180例新生儿高胆红素血症患儿的临床资料。结果治疗组患儿,临床总有效率为92.22%;对照组90例患儿,总有效率为71.11%;两组患儿的临床疗效经统计学分析,χ2值为43.20,P<0.05,有显著性差异。结论采用贝飞达和思密达联合治疗新生儿高胆红素血症的患儿临床疗效确切,值得推广应用。 Objective To investigate the clinical effect of combination of Beipidal and Smecta in the treatment of neonatal hyperbilirubinemia. Methods The clinical data of 180 neonates with hyperbilirubinemia admitted to our hospital in recent years were retrospectively analyzed. Results The total clinical effective rate was 92.22% in the treatment group and 90% in the control group, the total effective rate was 71.11%. The clinical efficacy of the two groups was statistically analyzed, the χ2 value was 43.20, P <0.05 Significant difference. Conclusion The combination of Befei Feida and Smectite in the treatment of neonatal hyperbilirubinemia is clinically effective and worthy of promotion.